About Index Trending news
Analyze
Pricing
Advaxis

Advaxis

Advaxis

Advaxis is a biotechnology company developing the next generation of cancer immunotherapies. $ADXS

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding
Post-IPO equity
$30,000,000
Jefferies, Guggenheim Securities, Cantor Fitzgerald
Employees

Team size

10+
Locations
HQ
Headquarters
Xconomy

Advaxis Inks Deal with Sellas to Develop New Cancer Immunotherapy

Robotics Health
$30,000,000 Post-IPO equity
New Jersey Business Magazine

Advaxis Secures $30M Direct Placement Financing

Stock markets
The Motley Fool

Why Advaxis, Inc. Stock Rose 19.6% in May

The Motley Fool

Profit-Taking Clobbers Advaxis, Inc. in April Despite Positive PR

Health Stock markets
The Motley Fool

Here's Why Advaxis Inc.'s Stock Roared Higher in March

The Motley Fool

Why Advaxis, Inc. Shares Are Soaring 16% Today

Health Stock markets
The Motley Fool

Why Advaxis Gained 20% in 2015 --

The Motley Fool

Why Advaxis, Inc Shares are Skyrocketing Today --

Health Stock markets
The Motley Fool

Here's Why Advaxis' Stock Gained 11% in October --